Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases  by Denadai, Rafael et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
Journal of Crohn's and Colitis (2013) 7, 517–524REVIEW ARTICLE
Induction or exacerbation of psoriatic
lesions during anti-TNF-α therapy for
inflammatory bowel disease: A systematic
literature review based on 222 cases☆
a, a bRafael Denadai ⁎, Fábio Vieira Teixeira , Flavio Steinwurz ,
Ricardo Romiti c, Rogério Saad-Hossne a
a Division of Coloproctology, Department of Surgery, School of Medical Sciences, University of the State of São Paulo (UNESP),
Botucatu, SP, Brazil
b Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
c Department of Dermatology, School of Medical Sciences, Universidade de São Paulo (USP), São Paulo, SP, BrazilReceived 2 February 2012; received in revised form 9 August 2012; accepted 10 August 2012☆ Research was performed at the Div
São Paulo (UNESP), Botucatu, SP, Braz
⁎ Corresponding author at: Paula Fab
E-mail address: denadai.rafael@ho
1873-9946 © 2012 European Crohn's an
http://dx.doi.org/10.1016/j.crohns.20KEYWORDS
Adalimumab;
Certolizumab;
Inflammatory bowel
disease;
Infliximab;
Psoriasis;
Biological therapy
Abstract
Background: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis
factor (TNF)-α therapy have been reported more frequently in recent years, but data related to
inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to
provide information about this adverse effect in patients with IBD who receive anti-TNF therapy.
Methods: Published studies were identified by a search of Medline, Embase, Cochrane, SciELO,
and LILACS databases.
Results: A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for
analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222
patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient
age was 26.50 years, and 70.72% of patients had no history of psoriasis. Patients developed
psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was
the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete
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518 R. Denadai et al.Conclusions: We found that psoriatic lesions occurred predominantly in adult patients with
Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients
can be managed conservatively without discontinuing anti-TNF-α therapy.
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In the last few years, tumor necrosis factor-alpha (TNF-α)
antagonists such as infliximab and adalimumab have revolu-
tionized the treatment of inflammatory bowel disease (IBD)1
and psoriasis.2 However, as the use of these biologic agents has
increased, reactivation of latent infections,3 cutaneous re-
actions (eczematous, neoplastic, granulomatous, and psoriatic
lesions),4,5 and other side effects6 have been documented.
These adverse cutaneous events include an increasing number
of paradoxical cases of psoriatic lesions (typical psoriasis and
psoriasiform lesions).7 Because some patients may present
with severe manifestations that require discontinuing the
use of biologic agents and subsequently risk aggravating the
underlying disease, physicians who treat these patients should
understand the clinical manifestations of this side effect and
therapeutic approaches.4,5
This paradoxical phenomenon has been described in the
literature.7 However, studies reporting psoriatic lesions in-
duced or exacerbated by TNF-α antagonists are largely hete-
rogeneous regarding the therapeutic agent involved, underlying
disease, treatment duration, personal and family history
of psoriasis, type of cutaneous eruption, and therapeutic
approaches and outcomes.4 Furthermore, in the largest study
available on this topic, patients with IBD comprised only 19.80%
of the study population, whereas rheumatologic patients com-
prised 73.91%.7
We therefore conducted a systematic literature review to
better understand the induction or exacerbation of psoriatic
lesions (typical psoriasis or psoriasiform lesions) by TNF-αantagonists in patients with IBD. We also discuss the possible
pathogenesis of this phenomenon.2. Methods
2.1. Strategy for article search and selection
We performed a systematic literature review by searching the
Medline (PubMed), Embase, Cochrane, SciELO, and LILACS
databases for articles published from January 2004 to October
2011 (the final literature reviewwas performed on October 30,
2011). To identify all relevant articles published in English
(clinical trials, case series and reports, and letters to the
editor) about psoriasis or psoriasiform lesions induced or
exacerbated by TNF-α antagonists (infliximab, adalimumab,
and certolizumab) in patients with IBD, we used the following
search terms: “adalimumab”, “anti-TNF-α”, “biological”,
“certolizumab”, “Crohn”, “inflammatory bowel disease”,
“IBD”, “infliximab”, “TNF inhibitor”, “tumor necrosis factor
alpha inhibitor”, and “ulcerative colitis” combined with the
terms “adverse event”, “cutaneous adverse effects”, “exac-
erbated”, “guttate”, “new-onset”, “paradoxical”, “plaque”,
“pustular” “psoriasis”, “side effect”, and “skin reactions”.
Relevant secondary references including abstracts published in
the annals of national and international congresses were also
included. Additionally, the reference lists of these articles
were examined to identify additional studies. Repeated studies
were considered only as a search source. Studies were selected
based on their titles (and abstracts if they were available) and
Table 1 Summary of demographic characteristics of 222
inflammatory bowel disease patients with psoriatic lesions
induced or exacerbated by tumor necrosis factor-alpha
antagonists published until October 2011.
Variables Patients
(No.=222)
Primary disease, no. (%)
CD 174 (78.38)
UC 25 (11.26)
IBD a 23 (10.36)
Disease associated, no. (%) 4.0 (1.80)
Gender, no. (%)
Female 107 (48.20)
Male 85 (38.29)
Unknown 30 (13.51)
Median age (years) 26.50 (8–54)
Unknown, no. (%) 35 (15.76)
Previous history of PS, no. (%)
No (de novo or induced PS) 157 (70.72)
Personal (exacerbated pre-existing PS) 20 (9.00)
Familiar 14 (6.31)
Unknown 31 (13.96)
UC, ulcerative colitis; CD, Crohn's disease; IBD, inflammatory
bowel disease; PS, psoriasis.
a Ulcerative colitis or Crohn's disease.
Table 2 Summary of main findings of 222 inflammatory
bowel disease patients with psoriatic lesions induced or
exacerbated by tumor necrosis factor-alpha antagonists
published until October 2011.
Variables Patients
(No.=222)
Anti-TNF-α involved, no. (%)
Infliximab 154 (69.37)
Adalimumab 50 (22.52)
Certolizumab 6.0 (2.70)
Anti-TNF-α a 12 (5.41)
Clinical latency (months) 13.79 (0.5–105)
Unknown, b no. (%) 40 (18.01)
519Psoriatic lesions during anti-TNF-a therapy for IBDretrieved for more detailed analysis. Theoretical review
articles that did not include additional cases were excluded,
as were studies that did not present information about IBD
separately from other diseases. Principles of the PICO strategy8
were adopted to ensure quality.
2.2. Data extraction and analysis
Two authors independently extracted data from each article,
and disagreements were resolved by consensus. Each study
was individually reviewed to identify data concerning age,
gender, personal and family history of psoriasis, biological
medication administered, duration of clinical latency, lesion
type (typical psoriasis or psoriasiform lesions), performance of
cutaneous biopsy, therapeutic approaches and outcomes, and
clinical IBD development. Nonspecific or unavailable informa-
tion was designated as unknown or unstated data. The se-
lected data were compiled in Microsoft Excel. Because this
information did not provide sufficient data evidence or meta-
analysis data, a simple descriptive analysis was performed.
3. Results
Using the inclusion and exclusion criteria, 47 publications
were identified (42 peer-reviewed papers and five meeting
abstracts) with a total of 222 patients with IBD who
experienced induction or exacerbation of psoriatic lesions
during anti-TNF-α therapy.9–55 The number of reported
cases has increased over the years (Fig. 1). However, the
reporting of various aspects of the cases was inconsistent
across studies. For example, gender, age, duration of
clinical latency, histopathological evaluation, therapeutic
approach, and clinical outcomes were not described in all
studies. The main demographic and clinical characteristics
of the 222 IBD patients are summarized in Tables 1 and 2.
3.1. Demographic aspects
In this review, 107 patients (48.20%) were female, and the
mean patient age was 26.50 years. Most patients did not
report a personal and/or family history of psoriasis (70.72%),
and most received anti-TNF-α therapy for the treatment ofFigure 1 Number of patients with inflammatory bowel
disease (IBD) who experienced psoriatic lesions induced or
exacerbated by anti-TNF-alpha therapy annually, based on
analysis of studies published through October 2011.
Type of cutaneous lesion, no. (%)
Psoriasiform lesions 124 (55.86)
Plaque-type PS 46 (20.72)
Pustular-type PS 8.0 (3.60)
More than one form of PS 8.0 (3.60)
Guttate-type PS 3.0 (1.35)
Diffuse-type PS 3.0 (1.35)
Other 10 (4.50)
Unknown 20 (9.00)
Cutaneous biopsy, no. (%)
Yes 75 (33.78)
No 76 (34.23)
Unknown 71 (31.98)
Anti-TNF-α, tumor necrosis factor-alpha antagonists; PS, psoriasis.
a Infliximab or adalimumab.
b Some studies have reported only the number of doses
administered.
Table 3 Summary of antipsoriatic therapeutic approaches
adopted in the 222 inflammatory bowel disease patients
with psoriatic lesions induced or exacerbated by tumor
necrosis factor-alpha antagonists published until October
2011.
Therapeutic approaches Patients
(No.=222)
Antipsoriatic therapy, a no. (%)
Topical corticosteroid 161 (72.52)
Vitamin D analogues 62 (27.93)
Phototherapy 24 (10.81)
Methotrexate 9.0 (4.05)
Systemic corticosteroid 5.0 (2.25)
Cyclosporine 3.0 (1.35)
Azathioprine+systemic corticosteroid 2.0 (0.90)
Azathioprine+mycophenolate mofetil 2.0 (0.90)
6-Mercaptopurine 1.0 (0.45)
Unknown 43 (19.37)
a Isolated or associated.
Table 4 Summary of therapeutic approaches and clinical
outcomes in the 222 inflammatory bowel disease patients
with psoriatic lesions induced or exacerbated by tumor
necrosis factor-alpha antagonists published until October
2011.
Management Patients
(No.=222)
Anti-TNF-α stopped, a no. (%)
Yes 86 (38.74)
No 87 (39.19)
Unknown 20 (9.00)
Anti-TNF-α switched, no. (%) 29 (13.06)
Clinical response related to anti-TNF-α, no. (%)
Completely resolved off anti-TNF-α 71 (31.98)
Partially resolved off anti-TNF-α 10 (4.50)
No resolution off anti-TNF-α 2.0 (0.90)
Unknown 3.0 (1.35)
Completely resolved on anti-TNF-α 64 (28.83)
Partially resolved on anti-TNF-α 7.0 (3.15)
No resolution on anti-TNF-α 2.0 (0.90)
Unknown 4.0 (1.80)
Resolved with anti-TNF-α switched 7.0 (3.15)
Recurrence or aggravation with anti-TNF-α
switched
21 (9.46)
Unknown 1.0 (0.45)
Anti-TNF-α, tumor necrosis factor-alpha antagonists.
a Isolated or associated.
520 R. Denadai et al.Crohn's disease (78.38%). In two patients (0.90%), IBD was
associated with spondyloarthritis, and in two others (0.90%),
IBD was associated with ankylosing spondylitis.18,26,51
3.2. TNF-α inhibitors
Three anti-TNF-α agents (infliximab, adalimumab, and certo-
lizumab) were responsible for the induction or exacerbation of
psoriatic lesions in patients with IBD, and 154 cases (69.37%)
were related to infliximab infusions. The mean latency time
between initiation of anti-TNF-α therapy and onset of the
psoriatic lesions was 13.79 months; however, latency was up
to 105 months in some cases.52
3.3. Clinical manifestations
Clinical presentation varied; psoriasiform lesions were themost
common form of psoriasis (55.86%), followed by typical plaque-
type lesions (20.72%), and pustular-type lesions (3.60%). Six
patients (2.70%) concomitantly presentedwith alopecia,40,41,55
one patient (0.45%) presented with palmoplantar pustulosis,49
and another patient (0.45%) presented with palmoplantar
pustulosis and psoriatic arthritis.47
3.4. Histopathological evaluation
Histopathological findings (epithelial hyperplasiawith acantho-
sis and hyperkeratosis, parakeratosis, lymphocytic infiltration
of the epidermis, and dilated capillaries) confirmed the diag-
nosis of psoriasis in 75 of the patients included in this review.
Less frequently, histopathological evaluations showed a liche-
noid aspect or spongiosis.29,31,38,44,51,55
3.5. Therapeutic approach
In 142 patients (63.96%), there was complete remission of
cutaneous lesions with different therapeutic approaches
(Tables 3 and 4). Topical corticosteroid treatment was the
antipsoriatic therapy used most often (72.52%). Anti-TNF-α
therapy was withdrawn in 86 patients (38.74%), resulting in
the complete resolution of 71 cases (31.98%). In 87 patients
(39.19%) for whom anti-TNF-α therapy was not suspended,
64 cases (28.83%) showed complete resolution of the lesions.
In 29 patients (13.06%), the anti-TNF-α agent that triggered
the psoriatic lesions was replaced with another anti-TNF-α
agent, with recurrence or aggravation of psoriatic lesions in
most cases (9.46%).
3.6. Management of the IBD following withdrawal of
TNF-α antagonist
In the studies16,18,27,33,37,41,44,42,45,47,48 describing IBD de-
velopment after discontinuation of TNF-α antagonists, gastro-
intestinal symptoms were controlled after the reintroduction of
infliximab16 or with the introduction of adalimumab,27,42,47,48
certolizumab,37 azathioprine,41 methotrexate,33,45 mesalazine
and corticosteroids,47 or methotrexate and corticosteroids,44
demonstrating the considerable heterogeneity of approaches
used after discontinuation of anti-TNF-α therapy. Psoriatic
lesions recurred in cases in which etanercept (used to treatassociated spondyloarthritis)18 and adalimumab27,42,48 were
given.4. Discussion
Recognition of the role played by the proinflammatory
cytokine TNF-α in the pathogenesis of autoimmune inflamma-
tory diseases (e.g., rheumatoid arthritis, IBD, and psoriasis)56
521Psoriatic lesions during anti-TNF-a therapy for IBDled to the development of TNF-α antagonists, which enabled
important advances in the treatment of these disabling chronic
diseases.57 However, paradoxical cases of psoriatic lesions
induced or exacerbated by anti-TNF-α agents have increasing-
ly been reported worldwide.7
Although the first case of infliximab-induced psoriasis
was described in a patient with Crohn's disease,9 most of the
evidence concerning this phenomenon was obtained from
the rheumatologic literature.58 An increasing number of IBD
patients have developed this cutaneous reaction, as de-
scribed in subsequent reviews,7,21,23,52,59 and the latest
review52 included 120 IBD patients. In the present review,
102 additional cases were included and analyzed for a total
of 222 IBD patients with this reaction.9–55 Five studies60–64
were not included in this review, because it was not possible
to extract only the data regarding the clinical development
of patients with IBD.
The present review showed that this adverse event was
more frequently reported in adult patients who did not have
a personal or family history of psoriasis, which is consistent
with the results of previous studies.7,58,59 Pustular psoriasis
was the most frequently described form of psoriasis (56%) in
a recent review7 that included patients with several un-
derlying diseases; however, among IBD patients, plaque-
type psoriasis was the most common form (61%). In contrast,
psoriasiform lesions were the most frequently reported
cutaneous lesions (55.86%) in our study. Because there is
no clear definition of psoriasiform lesion, many lesions
classified as psoriasiform may actually be the classic type of
psoriasis.
The review7 that analyzed the largest number of cases
(207 patients with different underlying diseases) reported
that the latency between anti-TNF-α administration and
onset of psoriatic lesions was extremely variable, similar to
what was observed in the present review. These cases in-
volved different TNF-α inhibitors (infliximab, adalimumab,
certolizumab, and etanercept); therefore, this paradoxical
effect is a reaction to a pharmacologic class of drugs rather
than a reaction to a specific drug.39,43 The present review
and previous reviews7,21,23,52,59 found that more cases
involved infliximab than any other anti-TNF-α agent, most
likely because this was the first biological agent available on
the market.52,59
The incidence of psoriasis among IBD patients can reach
11%, whereas it is only 1.5% in the general population.65,66 In
addition, the same genes (interleukin [IL]23R, IL12B, and
tyrosine kinase 2) predispose for both IBD and psoriasis,67
which may account for the high rate of psoriatic lesions in
IBD patients treated with anti-TNF-α agents.65–67 However,
several aspects of this phenomenon provide evidence for
the idea that it is a side effect of anti-TNF-α agents. These
include the absence of a personal or family history of psoriasis
in most reported cases, the increasing number of reported
cases, the temporal relationship between anti-TNF-α treat-
ment and the appearance of cutaneous lesions, and the
clinical improvement observed after discontinuation of ther-
apy and subsequent recurrence of psoriatic lesions after
switching to another anti-TNF-α agent.
Themechanism underlying the induction or exacerbation of
psoriatic lesions by anti-TNF-α antagonists is not clear.7,47,48
The most widely accepted hypothesis is based on an in-
teraction between increased interferon-alpha (IFN-α) levelsand reduction in TNF-α levels.7,31,41 Plasmacytoid dendritic
cells appear to induce psoriasis through IFN-α production.
These cells infiltrate the skin and produce IFN-α during the
initial phase of psoriasis.68,69 Plasmacytoid cells are normally
downregulated by TNF-α, which inhibits the maturation of
their hematopoietic precursors.39 Therefore, TNF-α inhibition
with the biological agent may result in uncontrolled IFN-α
production, thereby inducing or exacerbating psoriasis.39,41
Changed lymphocytes can also participate in this process
through the expression of the CXCR3 receptor.31,70
Several studies31,70,72 have reported findings that support
the role of IFN-α in the onset of psoriatic lesions during anti-
TNF-α therapy. One study31 reported high levels of the protein
MxA (marker for IFN signaling) in the inflammatory cells of
skin samples of psoriasis induced by anti-TNF-α. Another
study70 reported higher levels of IFN-α in the psoriatic lesions
of patients receiving anti-TNF-α therapy compared with spon-
taneous psoriasis lesions. Furthermore, there are cases of
psoriasis that developed or worsened after injection of re-
combinant IFN-α71 or topical application of imiquimod (a
potent IFN-α inducer).72
The time between anti-TNF-α administration and develop-
ment of psoriatic lesions varies widely,7 suggesting that an
environmental trigger may also be involved.52 In addition,
TNF-α antagonists have been administered to more than
2 million patients worldwide57 and cases of this adverse
cutaneous reaction are numerous, indicating that this phenom-
enon may be related to a genetic predisposition.7,36 Genetic
studies may be useful to identify genetically susceptible
patients and elucidate the immunopathogenic mechanism.7
Patients who have psoriatic lesions while undergoing anti-
TNF-α therapy must be evaluated by a dermatologist.42,54 A
detailed evaluation (clinical history, physical examination,
and cutaneous biopsy, if necessary)23,42 can eliminate acute
exanthematous pustulosis and other cutaneous diseases to
confirm the diagnosis of psoriasis.23,39 Although psoriatic
lesions in 34.23% of the IBD patients in this review were
clinically diagnosed, the authors of the present review and
others7,23,39 emphasize that it is important to correlate clinical
manifestations with histopathological findings,39 especially in
cases where lesions are present in sites that are not common
for psoriasis (e.g., face or flexor areas) or if the skin lesions
do not show the characteristics of psoriasis. Additionally,
infections, mechanical stressors, trauma (including emotional
trauma), and medications that trigger or exacerbate psoriasis
(e.g., beta-blockers, antimalarial drugs73) must also be
excluded.7,23,45
To date, no guidelines exist for treating cutaneous side
effects of TNF-α antagonists.54 A wide range of therapeutic
approaches have been used to treat IBD patients who develop
psoriatic lesions during anti-TNF-α therapy, and there is
disagreement as to whether discontinuation of the biological
agent is needed to achieve complete resolution of the lesions.
Regardless of the underlying disease, discontinuation of anti-
TNF-α therapy has culminated in the complete resolution of
cutaneous lesions in 24% of cases.7 Two reviews7,59 reported
that discontinuing anti-TNF-α therapy has been particularly
successful in IBD patients, and complete regression of cu-
taneous lesions was observed in 46% of patients, whereas
complete regression of cutaneous lesions was observed in only
17% of patients who continued treatment with the anti-TNF-α
agent.7 However, decisions must be cautious because only 18
522 R. Denadai et al.to 41 IBD patients were evaluated in these reviews.7,59 As the
number of reported cases increases, therapeutic approaches
and outcomes must be re-evaluated. With the inclusion of a
larger number of patients in the present review,we found that
the most common approach has been to continue anti-TNF-α
therapy despite adverse cutaneous reactions. Furthermore,
aggravation or recurrence of the psoriatic lesions was common
despite switching anti-TNF-α agents.
Based on the evidence that discontinuation of biological
therapy can aggravate gastrointestinal manifestations16,18,
27,33,37,41,44,42,45,47,48 and the analysis of the 47 articles
(222 patients)9–55included in this review, we believe that
most IBD patients with anti-TNF-α‐related psoriatic lesions
should be treated using a conventional approach (topical
corticosteroids, emollients, keratolytic therapy, vitamin D
analogs, phototherapy, methotrexate and/or cyclosporine)
while continuing the biological therapy. However, discon-
tinuation of anti-TNF-α therapy should be considered,
particularly in generalized, recalcitrant cases and when
quality of life is severely impaired. After resolution of the
cutaneous lesions, reintroduction of biological therapy must
be considered.
Patients with aggressive IBD who require discontinuation of
biological therapy may experience clinical deterioration.
Therefore, continuing biological therapy is recommended
along with standard treatment for psoriasis. However, alter-
native therapies for IBD (e.g., antibiotics, mesalazine, and
azathioprine) should be considered. Although replacing the
anti-TNF-α antagonist with another agent of the same class
has been successful in 31.5% of the analyzed cases, further
studies are still required to better characterize the efficacy
and safety of this approach.38,52,64
Our review has some limitations, such as its retrospective
design, lack of complete data in some studies, and heteroge-
neity of the studies included. It is important that prospective
cohort studies are designed to clarify the incidence and
prevalence of this adverse reaction and establish guidelines
for its diagnosis and treatment.
5. Conclusion
Although psoriatic lesions that are induced or exacerbated by
anti-TNF-α therapy in patients with IBD have been reported,
their immunopathogenic mechanisms have not yet been
elucidated. This cutaneous adverse reaction occurs predom-
inantly in adults with Crohn's disease receiving infliximab
therapy who have no personal or family history of psoriasis.
For most patients, the therapeutic approach should be based
on standard antipsoriatic therapy, without discontinuing or
switching the anti-TNF-α agent.
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